Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Spectral MD – executive interview

Spectral MD – executive interview

Spectral MD is a predictive analytics company, providing AI assessments on whether a wound will heal through its proprietary DeepView platform. The company primarily operates in the United States and has a growing presence in Europe. It is listed on London’s AIM market and is capitalised at £44m.

In this interview, Spectral MD’s vice president of marketing and commercialisation, Christine Marks, discusses the value DeepView provides for quickly and accurately diagnosing the healing and non-healing areas of a wound. Spectral MD will go to market, first in assessing diabetic foot ulcers and then in burn application. Christine elaborates on the market opportunity from being the only specialist AI company in these areas. She also describes the company’s key growth drivers and the investments being made to support Spectral MD’s long-term growth.

< Previous
Next >

You may also be interested in these:

TMT

VEON – executive interview with CFO Joop Brakenhoff

TMT

VEON – executive interview with CEO Kaan Terzioğlu

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free